Cantharidin: a double-edged sword in medicine and toxicology
Frontiers in Pharmacology · 17.09.2025 · 16
DOI: 10.3389/fphar.2025.1644186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.09.2025. Verfasst von Jie Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cantharidin (CTD), a natural terpenoid toxin secreted by blister beetles, acts as a potent inhibitor of protein phosphatase. As the principal active component of Mylabris, a traditional Chinese medicine, CTD has attracted considerable interest due to its dual properties, combining potent anti-tumor activity with significant toxicity. Contemporary pharmacological research demonstrates that CTD inhibits the growth and proliferation of diverse cancer cells lines. It exhibits antibacterial and antiparasitic properties, and demonstrates pesticidal activity in agricultural applications. Despite these benefits, CTD exhibits a prominent double-edged profile, marked by severe toxic effects, including cardiotoxicity, nephrotoxicity, gastrointestinal toxicity, and reproductive toxicity. Our prior research has identified the heart and liver as primary targets of CTD’s acute toxicity, where it induces apoptosis and necrosis of cardiomyocytes and hepatocytes. Recent efforts to mitigate its toxicity while preserving efficacy have focused on the structural modifications of CTD and the development of its derivatives. Additionally, CTD has been demonstrated to enhance anti-tumor efficacy when combined with other drugs, particularly against certain drug-resistant tumors. This review comprehensively evaluates CTD’s pharmacology and toxicology, synthesizes pertinent toxicological data, and explores strategies for toxicity reduction to guide future research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology and Center for Human Genome Research, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Prenatal Diagnosis Center, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Tian, T., Li, C., Liu, Y., Wang, Y., Liu, L., Liu, L., & Yao, Y. (2025). Cantharidin: a double-edged sword in medicine and toxicology. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1644186
Vancouver
Zhang J, Tian T, Li C, Liu Y, Wang Y, Liu L, et al. Cantharidin: a double-edged sword in medicine and toxicology. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1644186
BibTeX
@article{Zhang2025,
author = {Zhang, Jie and Tian, Tongtong and Li, Canyu and Liu, Yong and Wang, Yunyun and Liu, Ling and Liu, Liang and Yao, Yufeng},
title = {Cantharidin: a double-edged sword in medicine and toxicology},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1644186}
}
EUVIMED